Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T17:03:55.017Z.
Calculation as of: 2026-10-06T17:03:55.017Z.
Quote observation: 2026-10-06T17:00:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 772026cfaa68636964238f2a0be34d7b7ee81ab44c33f4f711fca00153048be4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Ultragenyx Pharmaceutical Inc.
Market Cap
$1.44B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.45B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.44B
Operating Cash Flow Yield
N/A
TTM Avg
14.73%
3Y Avg
14.73%
5Y Avg
14.73%
Market Cap
$1.46B
Operating Cash Flow Yield
10.79%
TTM Avg
10.55%
3Y Avg
6.87%
5Y Avg
5.24%
Market Cap
$1.42B
Operating Cash Flow Yield
1.28%
TTM Avg
0.67%
3Y Avg
0.67%
5Y Avg
1.44%
Market Cap
$1.45B
Operating Cash Flow Yield
5.70%
TTM Avg
8.38%
3Y Avg
5.38%
5Y Avg
4.20%
Market Cap
$1.42B
Operating Cash Flow Yield
3.76%
TTM Avg
4.59%
3Y Avg
4.10%
5Y Avg
4.07%
Market Cap
$1.47B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | $1.44B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.44B | N/A | 14.73% | 14.73% | 14.73% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 10.79% | 10.55% | 6.87% | 5.24% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 1.28% | 0.67% | 0.67% | 1.44% |
| Certara, Inc. (CERT)vs › | $1.45B | 5.70% | 8.38% | 5.38% | 4.20% |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 3.76% | 4.59% | 4.10% | 4.07% |
| GH Research PLC (GHRS)vs › | $1.48B | N/A | N/A | N/A | N/A |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.47B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
